Bart S. Hendriks
Impact in
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery
- Oncology top 5%
- HER2/EGFR in Cancer Research
Papers in
-
- Nanoparticle-Based Drug Delivery 7
- Oncology 10
- HER2/EGFR in Cancer Research 8
- PARP inhibition in cancer therapy 2
- Co-authors
- Douglas A. Lauffenburger (12 shared papers)H. Steven Wiley (4 shared papers)Thomas J. Wickham (12 shared papers)Elena Geretti (9 shared papers)Lee K. Opresko (2 shared papers)Shannon Curtis Leonard (7 shared papers)Helen Lee (12 shared papers)Daniel F. Gaddy (8 shared papers)
- Journals
- British Journal of Cancer (3 papers)Molecular Cancer Therapeutics (2 papers)CPT Pharmacometrics & Systems Pharmacology (2 papers)Molecular BioSystems (2 papers)Clinical Cancer Research (2 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Bart S. Hendriks
44 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 71
- Biomaterials 627
- Oncology 337
- Pharmacology 106
- Radiology, Nuclear Medicine and Imaging 170
- Modeling and Simulation 17
Countries citing papers authored by Bart S. Hendriks
This map shows the geographic impact of Bart S. Hendriks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart S. Hendriks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart S. Hendriks more than expected).
Fields of papers citing papers by Bart S. Hendriks
This network shows the impact of papers produced by Bart S. Hendriks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart S. Hendriks. The network helps show where Bart S. Hendriks may publish in the future.
Co-authors
The 25 scholars most cited alongside Bart S. Hendriks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 334 | |
| 2 | 2003 | 160 | |
| 3 | 2017 | 155 | |
| 4 | Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. | 2003 | 117 |
| 5 | 2009 | 117 | |
| 6 | 2018 | 111 | |
| 7 | 2016 | 110 | |
| 8 | 2021 | 109 | |
| 9 | 2006 | 103 | |
| 10 | 2012 | 99 | |
| 11 | 2013 | 78 | |
| 12 | 2008 | 77 | |
| 13 | 2021 | 67 | |
| 14 | 2004 | 65 | |
| 15 | 2012 | 60 | |
| 16 | 2018 | 59 | |
| 17 | 2003 | 56 | |
| 18 | 2013 | 55 | |
| 19 | 2015 | 54 | |
| 20 | 2018 | 54 |
About Bart S. Hendriks
Bart S. Hendriks is a scholar working on Biomaterials, Oncology, Pharmacology, Cell Biology and Rheumatology, having authored 44 papers that have together received 2.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (8 papers), Nanoparticle-Based Drug Delivery (7 papers), Drug-Induced Hepatotoxicity and Protection (4 papers), Radiopharmaceutical Chemistry and Applications (2 papers), Cancer therapeutics and mechanisms (2 papers), Rheumatoid Arthritis Research and Therapies (2 papers), Computational Drug Discovery Methods (2 papers) and PARP inhibition in cancer therapy (2 papers). The work is most often cited by research in Biomaterials (627 citations), Oncology (337 citations), Pharmacology (106 citations), Radiology, Nuclear Medicine and Imaging (170 citations) and Modeling and Simulation (17 citations). Bart S. Hendriks has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Douglas A. Lauffenburger, H. Steven Wiley, Thomas J. Wickham, Elena Geretti, Lee K. Opresko, Shannon Curtis Leonard, Helen Lee, Daniel F. Gaddy, Christopher W. Espelin and David de Graaf. Their work appears in journals such as British Journal of Cancer, Molecular Cancer Therapeutics, CPT Pharmacometrics & Systems Pharmacology, Molecular BioSystems and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.